- Home
- MIN vs DERM Comparison
MIN vs DERM Comparison
Compare MIN & DERM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIN | DERM |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 297.6M | 257.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MIN | DERM |
|---|---|---|
| Price | $2.60 | $8.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.67 |
| AVG Volume (30 Days) | ★ 225.8K | 82.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | ★ $56,134,000.00 |
| Revenue This Year | N/A | $17.48 |
| Revenue Next Year | N/A | $55.83 |
| P/E Ratio | $32.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.57 | $4.97 |
| 52 Week High | $2.73 | $9.56 |
Technical Indicators
Market Signals| Indicator | MIN | DERM |
|---|---|---|
| Relative Strength Index (RSI) | 48.44 | 51.55 |
| Support Level | $2.57 | $6.71 |
| Resistance Level | $2.62 | $8.71 |
| Average True Range (ATR) | 0.02 | 0.48 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 45.45 | 57.68 |
Price Performance
Historical ComparisonAbout MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About DERM Journey Medical Corporation
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.